Chemomab Therapeutics Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.02next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly8MTarget: Sufficient to fund operations through Q1 2027
Quarterly Operating Expenses Quarterly1.9MTarget: Maintain cost-containment measures below $2.0 million per quarter
Watch Items
- Strategic Partnering Agreement for NebokitugTrigger: Execution of a global or territorial licensing dealAction: Evaluate upfront cash, milestone structures, and cost-sharing percentages to assess dilution risk mitigation.
- Initiation of Phase 3 Pivotal Trial in Primary Sclerosing Cholangitis (PSC)Trigger: First patient dosed in the global Phase 3 trialAction: Monitor trial site activation, enrollment velocity, and capital burn rate relative to the cash runway.
Research as of 20 Jun 2026